News | September 21, 2021
Zydus agrees to sell Mifegest and Cytolog to Integrace
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Subscribe To Our Newsletter & Stay Updated
